AstraZeneca PLC (AZN)

業務介紹

阿斯利康公司(AstraZeneca PLC)是一家生物製藥公司,專注於處方藥物的發現、開發、製造和商業化。其上市產品包括:

腫瘤科:Calquence、Enhertu、Faslodex、Imfinzi、Iressa、Koselugo、Lumoxiti、Lynparza、Orpathys、Tagrisso和Zoladex。

心血管、腎臟和代謝疾病:Brilinta/Brilique、Bydureon/Byetta、BCise、Byetta、Crestor、Evrenzo、Farxiga/Forxiga、Komboglyze/Kombiglyze XR、Lokelma、Onglyza、Qtern和Xigduo/Xigduo XR。

呼吸和免疫:Bevespi Aerosphere、Breztri Aerosphere、Daliresp/Daxas、Duaklir Genuair、Fasenra、Pulmicort、Saphnelo、Symbicort和Tudorza/Eklira/Bretaris。

罕見疾病:Andexxa/Ondexxya、Kanuma、Soliris、Strensiq和Ultomiris。

其他產品包括Synagis(呼吸道合胞病毒)、Fluenz Tetra/FluMist Quadrivalent(流感)、Seroquel IR/Seroquel XR(精神分裂症雙相障礙)、Nexium和Losec/Prilosec(胃腸疾病),以及Vaxzevria和Evusheld(COVID-19)。

該公司通過分銷商和當地代表辦事處在英國、歐洲其他地區、美洲、亞洲、非洲和澳大拉西亞提供服務。它與Regeneron Pharmaceuticals、Neurimmune AG、Ionis Pharmaceuticals、Proteros Biostructures和Sierra Oncology有合作協議。該公司原名Zeneca Group PLC,於1999年4月更名為AstraZeneca PLC,於1992年註冊成立,總部位於英國劍橋。



AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

公司網址

https://www.astrazeneca.com